Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 101
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V95AEA03FAEEN
Leaflet:

Download PDF Leaflet

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2016, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.Vancomycin-Resistant Enterococcus faecium Infections.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Enterococcus faecium Infections Overview
Therapeutics Development
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies
Vancomycin-Resistant Enterococcus faecium Infections - Products under Investigation by Universities/Institutes
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
Alchemia Limited
Alvogen Korea Co., Ltd.
Aphios Corporation
C3 Jian, Inc
Cellceutix Corporation
Helix BioMedix, Inc.
Hsiri Therapeutics LLC
LegoChem Biosciences, Inc
Lytix Biopharma AS
MGB Biopharma Limited
MicuRx Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
NovoBiotic Pharmaceuticals, LLC
Oragenics, Inc.
Sealife PHARMA GMBH
Sentinella Pharmaceuticals, Inc.
TAXIS Pharmaceuticals, Inc.
Wockhardt Limited
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AM-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDM-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chrysophaentin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
closthioamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epimerox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HT-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCB-010371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCB-010699 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LTX-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-IV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OG-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ramoplanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-2078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Teixobactin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WCK-4086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
Featured News & Press Releases
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


LIST OF TABLES

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2016
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Limited, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alvogen Korea Co., Ltd., H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corporation, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by C3 Jian, Inc, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H2 2016
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H2 2016 96

LIST OF FIGURES

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2016
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: